Adjuvant solution for pandemic influenza vaccine production

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 43, 2012, Pages 17585-17590

  Clegg, Christopher H ^a   Roque, Richard ^a   Van Hoeven, Neal ^b   Perrone, Lucy ^a   Baldwin, Susan L ^b   Rininger, Joseph A ^c   Bowen, Richard A ^d   Reed, Steven G ^b,e  

^a TRIA Bioscience Corp   (United States)

^b INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^c Protein Sciences Corp   (United States)

^d Department of Environmental and Radiological Health Sciences   (United States)

^e Immune Design Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOPYRANOSYL LIPID ADJUVANT; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; UNCLASSIFIED DRUG; WATER OIL CREAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION; IMMUNE RESPONSE; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; INNATE IMMUNITY; MICROENVIRONMENT; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PROTECTION; SIGNAL TRANSDUCTION; TH1 CELL; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; FEMALE; FERRETS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C;

EID: 84867911549     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1207308109     Document Type: Article

References (33)

1. Cox MM, Hashimoto Y (2011) A fast track influenza virus vaccine produced in insect cells. J Invertebr Pathol 107(Suppl):S31-S41.
2. Treanor JJ, et al. (2011) Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trial. Vaccine 29:7733-7739.
3. Treanor JJ, et al. (2001) Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732-1737. (Pubitemid 32175735)
4. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354:1343-1351.
5. O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G (2011) MF59 adjuvant: The best insurance against influenza strain diversity. Expert Rev Vaccines 10:447-462.
6. Leroux-Roels G (2009) Prepandemic H5N1 influenza vaccine adjuvanted with AS03: A review of the pre-clinical and clinical data. Expert Opin Biol Ther 9:1057-1071.
7. Reed SG, Bertholet S, Coler RN, Friede M (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30:23-32.
8. Duthie MS, Windish HP, Fox CB, Reed SG (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239:178-196.
9. McKeage K, Romanowski B (2011) AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): A review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs 71:465-488.
10. Anderson RC, et al. (2010) Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces 75:123-132.
11. Coler RN, et al. (2011) Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 6:e16333.
12. Baldwin SL, et al. (2009) Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27:5956-5963.
13. Coler RN, et al. (2010) A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS ONE 5:e13677.
14. Chen J, et al. (1993) Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int Immunol 5:647-656. (Pubitemid 23209419)
15. Dormitzer PR, et al. (2011) Influenza vaccine immunology. Immunol Rev 239:167-177.
16. McKinstry KK, Strutt TM, Swain SL (2011) Hallmarks of CD4 T cell immunity against influenza. J Intern Med 269:507-518.
17. Calabro S, et al. (2011) Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29:1812-1823.
18. Seubert A, et al. (2011) Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci USA 108:11169-11174.
19. Baudner BC, et al. (2009) MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res 26:1477-1485.
20. Galli G, et al. (2009) Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 106:3877-3882.
21. Moris P, et al. (2011) H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 31:443-454.
22. Miao H, et al. (2010) Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol 84:6687-6698.
23. Gerhard W, Mozdzanowska K, Furchner M, Washko G, Maiese K (1997) Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev 159:95-103. (Pubitemid 27499862)
24. Waffarn EE, Baumgarth N (2011) Protective B cell responses to flu - no fluke! J Immunol 186:3823-3829.
25. Mozdzanowska K, Furchner M, Zharikova D, Feng J, Gerhard W (2005) Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: Evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies. J Virol 79:5943-5951. (Pubitemid 40617200)
26. Brown DM, Dilzer AM, Meents DL, Swain SL (2006) CD4 T cell-mediated protection from lethal influenza: Perforin and antibody-mediated mechanisms give a one-two punch. J Immunol 177:2888-2898. (Pubitemid 44277804)
27. + T cells in immunity to viruses. Nat Rev Immunol 12:136-148.
28. Belser JA, Katz JM, Tumpey TM (2011) The ferret as a model organism to study influenza A virus infection. Dis Model Mech 4:575-579.
29. Fang Y, et al. (2010) Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus. J Virol 84:8369-8388.
30. Sambhara S, Poland GA (2010) H5N1 Avian influenza: Preventive and therapeutic strategies against a pandemic. Annu Rev Med 61:187-198.
31. Middleton D, et al. (2009) Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J Virol 83:7770-7778.
32. Baras B, et al. (2011) Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets. Vaccine 29:2092-2099.
33. Kendal AP, Pereira MS, Skehel JJ (1982) Hemagglutination inhibition. Concepts and Procedures for Laboratory Based Influenza Surveillance, eds Kendal AP, Pereira MS, Skehel JJ (Centers for Disease Control and Pan-Am Health Org, Atlanta), pp B17-B35.